Signant Health Upgrades Clinical Supplies Management Platform
GxP Inventory available in two options for varying sponsor and CRO requirements.
Signant Health has relaunched its Signant SmartSignals Supplies GxP Inventory, an upgrade to its SmartSignals Supplies software. It available as either an Essential or Enterprise option, both of which are SaaS-based, with decisions revolving around company and/or trial size.
The Essential option enables sponsors to use a pre-configured system for inventory manufacturing, management, and QA/QP release. The Enterprise option provides advanced features for larger customers with internal supply chain capabilities to meet individualized requirements, sponsor-specific terminology/labels, and additional workflow/process options.
Reference: Signant Health Extends the Power of Clinical Supply Management Software to the Small and Mid-Size Market Through Updated and Enhanced Supplies Platform, Philadelphia, PA, July 10, 2023.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
